Connect with NCQA

twitter linkedin facebook google+ youtube pinterest

Report an Error

Use NCQA’s Feedback Form to report a broken link, or content error.

Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis

This HEDIS Measure

Assesses adults diagnosed with rheumatoid arthritis (RA) who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD).

So What?

RA is a chronic inflammatory disease in which the immune system attacks healthy joints.1 It causes inflammation and destruction of joints and can also damage organs.2 RA is progressive, but early intervention with DMARDs can help preserve function and prevent further damage to joints.2

References

  1. Centers for Disease Control and Prevention. 2012. “Rheumatoid Arthritis.” http://www.cdc.gov/arthritis/basics/rheumatoid.htm
  2. American College of Rheumatology. 2012. “Rheumatoid Arthritis.” http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp
tables
DMARD Treatment Rate
  Commercial Medicaid Medicare
Year HMO PPO HMO HMO PPO
2016 87.8 87.1 73.1 76.8 77.8
2015 88.3 87.8 71.7 77.1 78.8
2014 88.1 87.3 69.5 76.7 80.5
2013 88.1 87.2 70.6 76.2 80.2
2012 87.9 87.2 69.9 75.5 78.8
2011 87.6 86.7 68.9 72.7 77.2
2010 87.7 87.0 70.1 72.8 77.8
2009 86.4 86.6 70.5 72.3 76.4
2008 85.7 81.5 69.4 70.4 75.1
2007 85.3 78.9 68.1 68.7 73.5
2006 84.8 82.3 67.6 68.2 69.7